secwatch.observer — SEC 8-K summary
======================================

Issuer:     Boundless Bio, Inc. (BOLD)
CIK:        0001782303
Form:       8-K
Filed at:   2025-03-27T23:59:59+00:00
Accession:  0000950170-25-045722
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Boundless Bio Q4 & FY 2024 net loss $65.4M; cash $152.1M; BBI-355 data expected H2 2025
--------------------------------------------------------------------------------

- Net loss $16.4M in Q4 2024, full year $65.4M (vs $49.4M in 2023); R&D spend rose to $55.3M.
- Cash and investments $152.1M as of Dec 31, 2024; projected operating runway into 2027.
- BBI-355 Phase 1/2 POTENTIATE trial ongoing; initial proof-of-concept safety/activity data due H2 2025.
- Novel Kinesin program: development candidate nomination targeted for mid-2025, IND submission H1 2026.
- Appointed Dr. Robert Doebele as Chief Medical Officer in February 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1782303/000095017025045722/0000950170-25-045722-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1782303/000095017025045722/bold-20250327.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-045722

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer